A Phase III, Double Blind, Randomized Study to Evaluate Safety and Efficacy of BAL8557 Versus Voriconazole for Primary Treatment of Invasive Fungal Disease Caused by Aspergillus Species or Other Filamentous Fungi.
The purpose of this study is to compare the efficacy and safety of isavuconazole versus voriconazole in the treatment of patients with invasive aspergillosis.
Stanford is not currently accepting new patients for this trial. You may want to check clinicaltrials.gov to see if other locations are recruiting.
- drug : Voriconazole
- drug : Isavuconazole
Phase: Phase 3
Ages Eligible For Study:
- Patients must have proven, probable or possible invasive fungal disease caused by Aspergillus species or other filamentous fungi - Female patients must be non-lactating and at no risk for pregnancy